Characterize infections and outcomes developed in relapsed/refractory multiple myeloma (RRMM) patients treated with Teclistamab (SPOT)

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/1000000414
• EU PAS number:
  EUPAS1000000414
• Study ID:
  1000000414
• Official title and acronym:
  Characterize infections and outcomes developed in relapsed/refractory multiple myeloma (RRMM) patients treated with Teclistamab (SPOT)
• DARWIN EU® study:
  No
• Study countries:
  Portugal
• Study description:
  This is a retrospective, multicenter, observational study to primarily characterize the infections developed by triple class-exposed RRMM patients and their outcomes during Teclistamab treatment, in the Portuguese clinical practice.
• Study status:
  Ongoing

Study timelines

Date when funding contract was signed

Planned: 23/04/2024

Study start date

Planned: 27/02/2025

Actual: 27/02/2025

Data analysis start date

Planned: 14/02/2026

Date of final study report

Planned: 14/11/2026

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable